Praxis reports positive EMBRAVE Part A data for elsunersen; FDA grants priority review for relutrigine

Praxis Precision Medicines, Inc.

Elsunersen achieved 77% placebo-adjusted seizure reduction (p=0.015) in 9-patient Phase 1/2 trial.
57% of elsunersen patients had ≥28-day seizure freedom; improvements in sleep, motor function, attention.
Relutrigine NDA accepted for priority review by FDA with PDUFA target date of September 27, 2026.
Elsunersen well tolerated; no drug-related SAEs, no discontinuations, no neuroinflammation at doses up to 8 mg.
All 9 patients continued into open-label extension; efficacy sustained for up to one year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.